tirzepatide cv outcomes In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT Cardiovascular outcomes. Forest plot comparing

Links: FDA Warning Letter: Hims FDA Warning Letter: HersRead the warning letters for a complete description of violations

Their call-to-action includes: Build and support multidisciplinary teams of frontline clinicians, community partners, physiologists and behavioral and pharmaceutical scientists to address the knowledge gap in GLP-1RA effects in children and adolescents

Published May 28, 2024.

(1) Prevention from DPP-4 degradation

September 15, 2025: Study Finds Over Half of New Rybelsus Users Stop the Drug Within a Year A new Danish study found that more than half of new Rybelsus patients stopped using the semaglutide injections within a year after starting them